Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

VSV-GP BI 1831169

A recombinant, live-attenuated, oncolytic chimeric virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP), with potential immunomodulating and antineoplastic activities. Upon administration, VSV-GP BI 1831169 preferentially replicates in tumor cells. Due to defective antiviral host defense mechanisms in tumor cells, VSV-GP BI 1831169 is able to replicate in tumor cells without interference. This induces VSV-mediated cytolytic activity towards the tumor cells. In addition, viral infection stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In VSV-GP BI 1831169, the VSV-G glycoprotein is replaced with the Lymphocytic Choriomeningitis Virus glycoprotein in order to minimize the potential of neurotoxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:oncolytic virus BI 1831169
oncolytic virus VSV-GP BI 1831169
vesicular stomatitis virus-glycoprotein
vesicular stomatitis virus-GP BI 1831169
VSV-GP
Code name:BI 1831169
BI-1831169
BI1831169
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search